New tool may help prioritize high-risk infants for RSV immun

On the heels of a shortage of nirsevimab for infant respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) prevention, a new tool may help identify newborns at highest risk for developing serious RSV LRTI, according to research published at the ATS 2024 International Conference.

Related Keywords

United States , Netherlands , Vanderbilt University , Tennessee , Tinav Hartert , Brittneym Snyder , Niek Achten , Tebeb Gebretsadik , Centers For Disease Control Prevention , Erasmus University Medical Center , Division Of Allergy , Tennessee Medicaid Program , Department Of Biostatistics , International Conference , Vanderbilt University Medical Center , Critical Care Medicine , Vanderbilt University Medical , Disease Control , Principal Investigator Tina , Pediatric Impact , Clinical Prediction Tool ,